Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality
Joint Statement PSAAP Meeting 3 June 2021
Joint Statement PSAAP Meeting 3 June 2021

The PSAAP Group met virtually to discuss the draft Prescription Notice for 2021/22.
• PSAAP agreed that the 2021/22 Prescription Notice will be implemented via a voluntary variation to the PHOSA to take effect from 1 July 2021.
• The voluntary variation will invest over $56 million1 of new Ministry of Health and DHB funding into general practice teams and PHOs through the 2021/22 annual rate change process.
• A 2.78% rate increase will apply to First Contact, Immunisation Administration, Services to Improve Access, and Care Plus.
• A 2% rate increase will apply to Health Promotion, Management Services and Rural Workforce Retention.
• It was recognised that patient co-payment levels for non-Very Low Cost Access (non-VLCA) adults and young people 14 and over may increase by up to 2.78% from 1 July 2021 and that this may increase the co-payment differential with VLCA practices.
• It was acknowledged that additional investment was being made to keep the maximum co-payment thresholds for VLCA practices and eligible CSC holders at the existing level of $13 per visit for eligible children 14 to 17 years old and $19.50 per visit for eligible adult enrolees.
• It was acknowledged that investment was being made to keep the co-payments for general practice visits and fully funded prescriptions at zero cost for enrolled children under the age of 14 years at the point of care.
1 This is subject to variation due to demographic changes in PHO enrolment registers.